Minimal residue disease (MRD) in multiple myeloma

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) considers how detecting and monitoring minimal residue disease (MRD) in multiple myeloma may inform and tailor therapeutic decisions. Clinically important methods to determine MRD include flow cytometry and next-generation sequencing.

Share this video  
Similar topics